April 2, 2026
In part two of his Pharmaceutical Commerce interview series, Pleio CEO Michael Oleksiw reframes pharma’s adherence problem as fundamentally human — not logistical. From the industry’s persistent “one-and-done” challenge to the underestimated role of loneliness in early discontinuation, Oleksiw makes the case that lasting behavior change requires meeting patients emotionally before overwhelming them with tools, reminders, or information they aren’t yet ready to act on.
April 1, 2026
In his Pharma Live byline, Pleio CEO Michael Oleksiw puts empathetic AI to the test starting with a direct question to ChatGPT. The answer cuts to the heart of what the industry needs to hear: AI can simulate empathy, but it can’t feel it. In healthcare, where trust, emotional presence, and human judgment determine whether patients stay on therapy, that distinction isn’t semantic, it’s consequential.
April 1, 2026
In part one of his two-part Pharmaceutical Commerce interview series, Pleio CEO Michael Oleksiw unpacks the hidden barriers to adherence that legacy patient support programs were never built to detect — and makes the case that AI-powered insights are now giving pharma companies a clearer, faster window into why patients actually stop. With oral GLP-1 therapies reshaping the market, the cost of not knowing is growing.